Novartis Considers Joining Swiss Vaccines Firm Berna With Chiron
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm would have to outbid a roughly $450 mil. bid from Dutch biotech company Crucell.
You may also be interested in...
Crucell Inks European Distribution Deal With Sanquin For Cofact
Pact compliments April agreement with U.S. Bayer spin-off Talecris Biotherapeutics to distribute Prolastin.
Crucell Inks European Distribution Deal With Sanquin For Cofact
Pact compliments April agreement with U.S. Bayer spin-off Talecris Biotherapeutics to distribute Prolastin.
Crucell Gains Contract Manufacturing Company With SBL Acquisition
Acquisition, valued at $50.5 mil., is expected to complete on Nov. 23.